FHIR IG analytics

Resources that use this resource

No resources found

Resources that this resource uses

No resources found

Narrative

Note: links and images are rebased to the (stated) source

Source1

{
  "resourceType": "Evidence",
  "id": "6512",
  "meta": {
    "versionId": "3",
    "lastUpdated": "2026-08-06T09:26:00.989Z"
  },
  "text": {
    "status": "extensions",
    "div": "<!-- snip (see above) -->"
  },
  "extension": [
    {
      "url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status",
      "valueCodeableConcept": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type",
            "code": "active",
            "display": "Active"
          }
        ]
      }
    }
  ],
  "url": "https://fevir.net/resources/Evidence/6512",
  "identifier": [
    {
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code": "ACSN",
            "display": "Accession ID"
          }
        ],
        "text": "FEvIR Object Identifier"
      },
      "system": "https://fevir.net/FOI",
      "value": "6512",
      "assigner": {
        "display": "Computable Publishing LLC"
      }
    }
  ],
  "name": "OSFPreprint_PrimaryOutcomeMeasure_0_OutcomeAnalysis_0_BetweenGroupAnalysis_OG000_OG001",
  "title": "Percentage of Participants With Clinical Recovery Within 14 Days After Randomization Statistical Analysis for Nigella Sativa Oil vs Control in Nigella Sativa for COVID-19 OSF Preprint",
  "citeAs": "Percentage of Participants With Clinical Recovery Within 14 Days After Randomization Statistical Analysis for Nigella Sativa Oil vs Control in Nigella Sativa for COVID-19 OSF Preprint [Database Entry: FHIR Evidence Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 6512. Revised 2021-07-19. Available at: https://fevir.net/resources/Evidence/6512. Computable resource at: https://fevir.net/resources/Evidence/6512#json.",
  "status": "active",
  "date": "2021-07-19T21:20:42.620Z",
  "author": [
    {
      "name": "Brian S. Alper"
    }
  ],
  "publisher": "Computable Publishing LLC",
  "contact": [
    {
      "telecom": [
        {
          "system": "email",
          "value": "support@computablepublishing.com"
        }
      ]
    }
  ],
  "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
  "variableDefinition": [
    {
      "description": "Adult symptomatic patients with mild COVID-19 were recruited between May and August 2020 from King Abdulaziz University Hospital in Jeddah, Saudi Arabia.",
      "variableRole": "population",
      "observed": {
        "reference": "Group/5224",
        "type": "Group"
      },
      "intended": {
        "reference": "Group/189713",
        "type": "Group",
        "display": "NCT04401202 Eligibility Criteria"
      }
    },
    {
      "description": "Nigella Sativa Oil (NSO)",
      "variableRole": "exposure",
      "observed": {
        "display": "supplementation with oral capsules of NSO (MARNYS® Cuminmar 500 mg twice daily for 10 days) plus standard of care"
      }
    },
    {
      "description": "Control",
      "variableRole": "exposure",
      "observed": {
        "display": "standard of care medications alone"
      }
    },
    {
      "description": "proportion of patients recovered (free of symptoms for 3 days) within 14 days after randomization",
      "variableRole": "outcome",
      "observed": {
        "reference": "EvidenceVariable/5269",
        "type": "EvidenceVariable",
        "display": "Percentage of Participants With Clinical Recovery Within 14 Days After Randomization"
      }
    }
  ],
  "statistic": [
    {
      "description": "There were 47 patients in the treatment group (NSO) and 47 patients in the control group. The proportion of patients recovered in the treatment group was significantly higher than the control group, 37 (79%) versus 21 (45%) (p=0.001).",
      "numberAffected": 58,
      "sampleSize": {
        "numberOfStudies": 1,
        "knownDataCount": 94
      },
      "attributeEstimate": [
        {
          "type": {
            "coding": [
              {
                "system": "http://terminology.hl7.org/CodeSystem/attribute-estimate-type",
                "code": "C44185",
                "display": "P-value"
              }
            ]
          },
          "quantity": {
            "value": 0.001
          }
        }
      ]
    }
  ]
}